Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-26
2008-09-23
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000, C544S232000
Reexamination Certificate
active
07427624
ABSTRACT:
The invention is related to phosphorus substituted purine nucleoside phosphorylase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5413996 (1995-05-01), Bodor
patent: 5493030 (1996-02-01), Morgans Jr. et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5633279 (1997-05-01), Morgans et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5670497 (1997-09-01), Bold et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5750343 (1998-05-01), Maag et al.
patent: 5750493 (1998-05-01), Schinazi et al.
patent: 5811422 (1998-09-01), Lam et al.
patent: 5874577 (1999-02-01), Chen et al.
patent: 5914332 (1999-06-01), Chen et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6174888 (2001-01-01), McQuire et al.
patent: 6312662 (2001-11-01), Robinson et al.
patent: 6319946 (2001-11-01), Hale et al.
patent: 6395763 (2002-05-01), Stamos et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6767900 (2004-07-01), Ubasawa et al.
patent: 2001/0031773 (2001-10-01), Camden
patent: 2002/0119443 (2002-08-01), Becker et al.
patent: 2003/0109498 (2003-06-01), Yuasa et al.
patent: 2004/0121316 (2004-06-01), Birkus et al.
patent: 2004/0167096 (2004-08-01), Cheng et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 441 192 (1991-01-01), None
patent: 0 465 297 (1992-01-01), None
patent: 0 531 597 (1993-03-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 786 455 (1997-07-01), None
patent: 0 852 233 (1998-07-01), None
patent: 0 919 562 (1999-06-01), None
patent: 1 295 879 (2003-03-01), None
patent: WO 88/06158 (1988-08-01), None
patent: WO91/19721 (1991-12-01), None
patent: WO 92/00988 (1992-01-01), None
patent: WO 92/18520 (1992-10-01), None
patent: WO 93/12123 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 96/14314 (1996-05-01), None
patent: WO 96/40156 (1996-12-01), None
patent: WO 97/01558 (1997-01-01), None
patent: WO 98/04569 (1998-02-01), None
patent: WO 98/11906 (1998-03-01), None
patent: WO 98/15563 (1998-04-01), None
patent: WO 99/33815 (1999-07-01), None
patent: WO 99/62921 (1999-12-01), None
patent: WO 00/04033 (2000-01-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/17982 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/39724 (2001-06-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/64693 (2001-09-01), None
patent: WO 01/39724 (2001-10-01), None
patent: WO 01/96329 (2001-12-01), None
patent: WO 01/96354 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06292 (2002-01-01), None
patent: WO 02/08241 (2002-01-01), None
patent: WO 02/14344 (2002-02-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/103008 (2002-12-01), None
patent: WO 03/028737 (2003-04-01), None
patent: WO 03/050129 (2003-06-01), None
patent: WO 03/059255 (2003-07-01), None
patent: WO 03/064383 (2003-08-01), None
patent: WO 03/066005 (2003-08-01), None
patent: WO 03/080078 (2003-10-01), None
patent: WO 02/103008 (2003-11-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 2004/096234 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2005/011709 (2005-02-01), None
patent: WO 2005/011709 (2005-02-01), None
patent: WO 2004/096818 (2005-04-01), None
Allen, Lee F. et al., CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK),Seminars in Oncology, Oct. 2003, pp. 105-116, vol 30, No. 5, Elsevier. Inc.
Bantia, Shanta et al., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent,International Immunopharmacology, 2001, pp. 1199-1210, Elsevier Science B.V.
Beauchamp, Lilia M., et al., Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase,Journal of Medicinal Chemistry, 1996, pp. 949-956, American Chemical Society.
Bohani D. W. et al., A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection,Bioorganic&Medicinal Chemistry Letters, 2004, vol. 14.
Bzowska, Agnieszka et al., Purine nucleoside phosphorylases: properties, functions, and clinical aspects,Pharmacology&Therapeutics, 2000, pp. 349-425, vol. 88, Elsevier Science Inc.
Chapman, H. et al., Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, vol. 20, Nos. 4-7, Marcel Dekker, Inc.
Clark, Jeremy L. et al., Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
Conklyn, Maryrose et al., The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing,Journal of Leukocyte Biology, Dec. 2004, pp. 1-8, vol. 76, The Society for Leukocyte Biology.
De Clereq, E., Highlights in the Development of New Antiviral Agents,Mini Reviews in Medicinal Chemistry, 2002, 163-175, vol. 2, No. 2., Bentham Science Publishers, Ltd.
Evans, Gary B., Exploring Structure—Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase,J. Med. Chem., 2003, 3412-3423, vol. 46, No. 15, American Chemical Society.
Gumina, Giuseppe et al., Advances in antiviral agents for hepatitis B virus,Antiviral Chemistry&Chemotherapy, 2001, 93-112, vol. 12, Suppl. 1, International Medical Press.
Gobec, S. et al., Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall,Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14.
Hegedus, Louis S. et al., Synthesis of 4′-Methyl and 4′-cyano Carbocyclic 2′,3′-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones,J. Org. Chem., 2004, 8492-8495, vol. 69, No. 24, American Chemical Society.
Herczegh P., et al., Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials,J. Med. Chem., 2002, vol. 45.
Hirabayashi, Hideki et al., Bone-Specific Drig Delivery Systems,Clinical Pharacokinetics, 2003, 1319-1330, vol. 42, No. 15.
Holy A. et al., Synthesis,Cllect. Czech. Chem. Commun., 1989, vol. 54, pp. 2190-2210.
Jain, Jugnu et al., Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor,Journal of Pharmacology and Experimental Therapeutics, 2002, 1272-1277, vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
Karpenko, Inna L. et al., Synthesis and Antitherpetic Activity of Acyclovir Phosphonates,Nucleosides, Nucleotides&Nucleic Acids, 2003, 319-328, vol. 22, No. 3, Marcel Dekker, Inc.
Kato, Keisuke et al., Stereoselective synthesis of 4′ -.alpha.-alkyclcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure,Chemical&Pharmaceutical Bulletin, 1999, 1256-1264, vol. 49, No. 9, Pharmaceutical Society of Japan.
Kato, Keisuke et al., Enantio- and diastereoselective synthesis of 4′-α-substituted carbocyclic nucleosides, Tetrahedron:Asymmetry, 1998, 911-914, vol. 9, Elsevier Science Ltd.
Kilpatrick, J. Michael, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2′-deoxyguanosine in primates,International Immunopharmacology, 2003, 541-548, vol. 3, Elsevier Science B.V.
Kim, Choung UN et al., Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, J. Org. Chem., 1991, 2642-2647, vol. 56, No. 8, American Chemical Society.
Kinsky, Stephen C. et al., Inhib
Chen James M.
Chen Xiaowu
Cho Aesop
Chong Lee S.
Fardis Maria
Gilead Sciences, Inc.
Shiao Rei-Tsang
Viksnins Harris & Padys PLLP
LandOfFree
Purine nucleoside phosphorylase inhibitory phosphonate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine nucleoside phosphorylase inhibitory phosphonate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine nucleoside phosphorylase inhibitory phosphonate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981178